Invenio Imaging Strengthens Board with Experienced Technology Leaders
Invenio Imaging, a pioneer in fresh tissue imaging and AI-enabled diagnostics, today announced strategic additions to its governing body. Adrian Whitford has been appointed as an Independent Board Director, while Biao He of Oak BioCapital and John Seamans of the Michigan Biomedical Venture Fund join the board. The appointments underscore Invenio Imaging’s commitment to advancing its AI-driven imaging platform and expanding its partnerships in venture funding and strategic collaborations.
Adrian Whitford Joins as Independent Board Director
Whitford brings decades of leadership in technology, commercial strategy, and scaling high-growth life sciences companies. His governance experience spans complex, multi-stakeholder environments, with a track record of guiding innovative ventures from early-stage development to market adoption. As an Independent Board Director, Whitford will focus on strategic growth, risk management, and governance practices that align with Invenio Imaging’s long-term objectives in AI-powered tissue analysis and imaging workflows.
What Whitford Brings to Invenio Imaging
- Proven ability to scale technology companies through strategic partnerships and commercial execution.
- Deep experience in boards, risk oversight, and corporate governance standards.
- Insights into navigating regulatory landscapes, reimbursement pathways, and market access for imaging technologies.
New Board Members from Oak BioCapital and Michigan Biomedical Venture Fund
The board additions reflect a strengthened collaboration between Invenio Imaging and leading investment groups focused on bio-tech innovation. Biao He, representing Oak BioCapital, and John Seamans, representing the Michigan Biomedical Venture Fund, bring diverse perspectives on early-stage financing, portfolio strategy, and the practical needs of companies commercializing AI-enabled imaging and diagnostic tools.
Biao He (Oak BioCapital)
Oak BioCapital’s involvement signals a continued emphasis on supporting ventures that merge biology with computational analytics. He’s expected to contribute insights on operational scale, capital efficiency, and the path to clinical adoption for imaging technologies that rely on artificial intelligence to deliver faster and more precise diagnostic results.
John Seamans (Michigan Biomedical Venture Fund)
Seamans brings a strong background in venture funding for biomedicine and a track record of guiding startups through clinical validation, regulatory milestones, and market entry. His perspective will help align Invenio Imaging’s product roadmap with real-world clinical workflows and the needs of healthcare providers seeking improved tissue analysis through AI-enabled imaging.
<h2 positioned for Growth: The Road Ahead for Invenio Imaging
Invenio Imaging aims to accelerate the deployment of its fresh tissue imaging solutions powered by artificial intelligence. The new board composition is designed to guide strategic initiatives, including product development, potential collaborations with hospitals and research centers, and scaled commercialization in key markets. By integrating the expertise of Whitford, He, and Seamans, Invenio Imaging intends to enhance governance, expand its investor relations, and strengthen pathways to clinical impact.
About Invenio Imaging
Invenio Imaging develops AI-powered platforms that deliver high-resolution, real-time imaging of fresh tissue to support clinical decision-making, research, and intraoperative workflows. The company’s technology focuses on rapid, accurate tissue analysis, enabling clinicians to make informed decisions with confidence and speed.
Forward-Looking Statements
This announcement contains forward-looking statements about the company’s strategic direction, governance, and growth trajectory. Actual results may differ due to factors including market dynamics, regulatory developments, and execution of planned initiatives. Invenio Imaging undertakes no obligation to update or revise these statements.
